Mindstrong Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Total Funding:$160M
Industry:Biotech
Founded:N/A
Lead Investor(s):General Catalyst

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Mindstrong's estimated annual revenue is currently $24.5M per year.(?)
  • Mindstrong received $31.0M in venture funding in January 2019.
  • Mindstrong's estimated revenue per employee is $155,000
  • Mindstrong's total funding is $160M.

Employee Data

  • Mindstrong has 158 Employees.(?)
  • Mindstrong grew their employee count by -3% last year.
  • Mindstrong currently has 27 job openings.

Founded by three of the world's leading authorities in computer science, neuroscience and medicine, Mindstrong is redefining behavioral healthcare by reimagining how providers will diagnose and manage neuropsychiatric and neurodegenerative disorders. Mindstrong has developed the first ever digital brain biomarkers applying machine intelligence to human-computer interaction patterns that can be captured passively from smartphone use. Mindstrong's patented digital biomarkers and digital phenotyping will for the first time enable ecological and continuous measure of neuropsychological function, providing physicians, healthcare systems and payers insight not previously possible and empowering care teams to better diagnose and treat neuropsychiatric and neurodegenerative conditions. Mindstrong is participating in several large clinical trials with pharma, health care systems, and NIH funded research. Founders: CEO and Founder, Dr. Paul Dagum is a visionary who has built the company from the ground up, bringing a combination of stellar business acumen and extensive R&D, to positively impact patient outcomes. Dr. Tom Insel is one of the world's leading authorities on mental health. He is the former director of the National Institute of Mental Health and led neuroscience at Verily. Dr. Rick Klausner has an incredible track record of building healthcare companies in addition to his tenure as the director of the National Cancer Institute.

keywords:N/A